Nalaganje...
Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
The development of imatinib has revolutionized the treatment of chronic myeloid leukemia. Follow-up analysis of IRIS trial participants continues to demonstrate durable responses for imatinib at 400 mg/day. However, 10%–15% of patients with chronic myeloid leukemia will become imatinib-resistant or...
Shranjeno v:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2011
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3085241/ https://ncbi.nlm.nih.gov/pubmed/21556318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMR.S11948 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|